VANCOUVER, British Columbia, June 30, 2004 (PRIMEZONE) -- BioCurex Inc. (Pink Sheets:BOCX) wishes to advise its shareholders that the Company is moving forward in its process to re-establish quotation on the OTC:BB. BioCurex has been diligent in its commitment to this process and shares the frustration of many investors who have indicated astonishment that we have had to undergo this lengthy administrative course. We appreciate the support we have received and are confident that our investors' patience will be rewarded with further corporate advances.
The Company also wants to reassure its shareholders that it continues to move effectively in the scientific and business arenas and anticipates further updates in the near term. BioCurex is strongly committed to its RECAF technology which has demonstrated a very significant and consistent ability to detect many types of cancer. We are confident in our direction and capability to introduce our diagnostic tests to the world markets.
About BioCurex:
BioCurex, Inc. is a biotechnology company that is developing products based on patented/proprietary technology in the areas of cancer diagnosis, tumor imaging and therapeutics. The technology identifies a cancer marker known as RECAF(tm), which is found on malignant cells from a variety of cancer types but is absent in most normal or benign cells. To find out more about BioCurex (Pink Sheets:BOCX), visit our website at www.biocurex.com.
Note:
The Company has not authorized the release of this information in any form that contravenes the Communication Act and will not be responsible for unsolicited massive distribution of this material by e-mail or facsimile by unauthorized parties. Statements in this press release, which are not historical facts, are "forward-looking statements" within the meaning given to that term in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results could differ materially from expected results.